Additional Information
Book Details
Abstract
This issue provides much needed updates since Dr. Sheinfeld’s issue published in 2007. Dr. Lin has assembled expert authors to provide clinicians with the full breadth of clinical updates on testicular cancer. New to this issue are articles on clinical outcomes, survivorship, and several articles on the management of Nonseminomatous Germ Cell Tumors.
Table of Contents
| Section Title | Page | Action | Price |
|---|---|---|---|
| Front Cover | Cover | ||
| Testicular Cancer | i | ||
| Copyright\r | ii | ||
| Contributors | v | ||
| Contents | ix | ||
| Urologic Clinics Of North America\r | xiii | ||
| Foreword\r | xv | ||
| Preface | xvii | ||
| Epidemiology and Diagnosis of Testis Cancer | 269 | ||
| Key points | 269 | ||
| Epidemiology | 269 | ||
| Risk factors for testis cancer | 270 | ||
| Personal History | 270 | ||
| Cryptorchidism | 270 | ||
| Family History | 270 | ||
| Intratubular Germ Cell Neoplasia | 270 | ||
| Race | 270 | ||
| Geography | 271 | ||
| Environmental Exposures | 271 | ||
| Infertility | 271 | ||
| Microcalcifications | 271 | ||
| Types of germ cell tumors | 271 | ||
| Screening | 271 | ||
| Presentation and diagnosis | 271 | ||
| Initial Presentation | 271 | ||
| History and Physical Examination | 272 | ||
| Imaging | 272 | ||
| Laboratory Testing | 272 | ||
| Staging | 273 | ||
| Metastatic spread | 273 | ||
| Prognosis | 274 | ||
| Summary | 274 | ||
| References | 274 | ||
| Intratubular Germ Cell Neoplasia of the Testis, Bilateral Testicular Cancer, and Aberrant Histologies | 277 | ||
| Key points | 277 | ||
| Introduction | 277 | ||
| Intratubular germ cell neoplasia | 278 | ||
| Risk Factors of Intratubular Germ Cell Neoplasia | 278 | ||
| Pathogenesis of Intratubular Germ Cell Neoplasia | 279 | ||
| Diagnosis of Intratubular Germ Cell Neoplasia | 279 | ||
| Prognosis of Intratubular Germ Cell Neoplasia | 279 | ||
| Treatment of Intratubular Germ Cell Neoplasia | 280 | ||
| Bilateral testicular germ cell tumor | 280 | ||
| Aberrant testicular histologies | 281 | ||
| Summary | 282 | ||
| References | 283 | ||
| Management of Low-Stage Testicular Seminoma | 287 | ||
| Key points | 287 | ||
| Introduction | 287 | ||
| Epidemiology | 287 | ||
| Histologic Subtypes | 287 | ||
| Patterns of Spread | 288 | ||
| Clinical evaluation | 288 | ||
| Presentation and Initial Evaluation | 288 | ||
| Serum Tumor Markers | 288 | ||
| Orchiectomy | 289 | ||
| Imaging | 290 | ||
| Staging and Risk Stratification | 290 | ||
| Management of clinical stage I seminoma | 290 | ||
| Surveillance | 290 | ||
| Outcomes | 290 | ||
| Surveillance protocols | 291 | ||
| Radiation exposure with surveillance | 292 | ||
| Patient adherence | 292 | ||
| Radiotherapy | 292 | ||
| Evolution of radiation therapy | 292 | ||
| General radiotherapy considerations | 293 | ||
| Toxicity | 293 | ||
| Adjuvant Single-Agent Carboplatin | 293 | ||
| Outcomes | 293 | ||
| Toxicity | 294 | ||
| Cost Considerations | 294 | ||
| Patterns of Failure | 294 | ||
| Risk-Adapted Management | 294 | ||
| Management of clinical stage IIA seminoma | 294 | ||
| Radiotherapy | 294 | ||
| Chemotherapy | 295 | ||
| Follow-up regimens | 295 | ||
| References | 295 | ||
| Management of Stage I Nonseminomatous Germ Cell Tumors | 299 | ||
| Key points | 299 | ||
| Epidemiology and presentation | 299 | ||
| Retroperitoneal workup and risk stratification | 300 | ||
| Imaging | 300 | ||
| Histopathologic Risk Factors | 300 | ||
| Management of stage I nonseminomatous germ cell tumor | 301 | ||
| Active Surveillance | 301 | ||
| Retroperitoneal Lymph Node Dissection | 303 | ||
| Primary Chemotherapy | 305 | ||
| Summary | 306 | ||
| References | 307 | ||
| The Evolution and Technique of Nerve-Sparing Retroperitoneal Lymphadenectomy | 311 | ||
| Key points | 311 | ||
| Introduction | 311 | ||
| Anatomy and physiology of ejaculation | 312 | ||
| Patient selection for nerve-sparing techniques | 312 | ||
| Technique | 314 | ||
| Outcomes | 316 | ||
| Antegrade Ejaculation | 316 | ||
| Fertility | 317 | ||
| Summary | 318 | ||
| References | 318 | ||
| Minimally Invasive Retroperitoneal Lymphadenectomy | 321 | ||
| Key points | 321 | ||
| Introduction | 321 | ||
| Indications for retroperitoneal lymphadenectomy | 321 | ||
| Clinical Stage I Nonseminomatous Germ Cell Tumor | 321 | ||
| Clinical Stage IIa Nonseminomatous Germ Cell Tumor Without Elevated Tumor Marker: S0 | 322 | ||
| Indications for postchemotherapy retroperitoneal lymphadenectomy | 322 | ||
| Postchemotherapy Retroperitoneal Lymphadenectomy in Advanced Seminomas | 322 | ||
| Postchemotherapy Retroperitoneal Lymphadenectomy in Advanced Nonseminomatous Germ Cell Tumor | 322 | ||
| Technique | 323 | ||
| Template | 323 | ||
| Approach | 324 | ||
| Laparoscopic Transperitoneal | 324 | ||
| Laparoscopic Extraperitoneal | 324 | ||
| Follow-up | 326 | ||
| Outcomes | 326 | ||
| Complications | 326 | ||
| Future considerations on robotic retroperitoneal lymphadenectomy | 326 | ||
| Summary | 326 | ||
| References | 327 | ||
| The Role of Postchemotherapy Surgery in Germ Cell Tumors | 331 | ||
| Key points | 331 | ||
| Classifying postchemotherapy retroperitoneal lymph node dissection | 331 | ||
| Rationale for surgery after chemotherapy | 332 | ||
| Indications for postchemotherapy retroperitoneal lymph node dissection | 335 | ||
| Patient selection | 335 | ||
| Mass Less Than 1 cm | 335 | ||
| Refractory Germ Cell Tumor | 336 | ||
| Extent of dissection | 336 | ||
| Minimally invasive postchemotherapy–retroperitoneal lymph node dissection | 337 | ||
| Adjuvant procedures | 338 | ||
| Morbidity | 338 | ||
| Outcomes | 339 | ||
| Follow-up | 339 | ||
| References | 339 | ||
| Desperation Postchemotherapy Retroperitoneal Lymph Node Dissection for Metastatic Germ Cell Tumors | 343 | ||
| Key points | 343 | ||
| Introduction | 343 | ||
| Elevated serum tumor markers following first-line chemotherapy for germ cell tumor | 343 | ||
| Elevated serum tumor markers following second-line chemotherapy for germ cell tumor | 344 | ||
| Histologic Findings at the Time of Desperation Retroperitoneal Lymph Node Dissection | 344 | ||
| Clinical Outcome Following Desperation Retroperitoneal Lymph Node Dissection | 345 | ||
| Summary | 345 | ||
| References | 345 | ||
| Chemotherapy for Good-Risk Nonseminomatous Germ Cell Tumors | 347 | ||
| Key points | 347 | ||
| Concept 1: cisplatin combination chemotherapy can cure even advanced germ cell patients | 347 | ||
| Concept 2: three cycles of combined cisplatin, bleomycin, and etoposide is associated with high cure rates for good-risk no ... | 349 | ||
| Controversy 1: is bleomycin necessary? | 349 | ||
| Concept 3: bleomycin pulmonary toxicity is relatively rare and some factors may facilitate selection of patients at higher ... | 350 | ||
| Controversy 2: is the toxicity profile of four cycles of bleomycin-free cisplatin and etoposide better than three cycles of ... | 350 | ||
| Concept 4: carboplatin is inferior in achieving cure for nonseminomatous germ cell tumors | 351 | ||
| Concept/controversy 5: addressing survivorship needs of patients with germ cell tumor | 351 | ||
| Cardiovascular Effects | 351 | ||
| Secondary Malignancies | 353 | ||
| Neurologic Toxicities | 353 | ||
| Renal Toxicity | 353 | ||
| Gonadal Effects | 353 | ||
| Psychosocial Effects | 354 | ||
| Summary | 354 | ||
| References | 354 | ||
| Late Relapse of Testicular Germ Cell Tumors | 359 | ||
| Key points | 359 | ||
| Introduction | 359 | ||
| Clinical presentation and detection of late relapse | 360 | ||
| Detection of Late Relapse | 360 | ||
| Time to Late Relapse | 360 | ||
| Patterns of Late Relapse | 360 | ||
| Clinical outcomes and predictors of survival in late relapse | 360 | ||
| Late Relapse in Patients Initially Managed with Surveillance | 361 | ||
| Late Relapse After Adjuvant Radiotherapy or Chemotherapy for Clinical Stage I Seminoma | 361 | ||
| Late Relapse in Patients Initially Presenting with Low-Stage Nonseminomatous Germ Cell Tumors Managed with Retroperitoneal ... | 362 | ||
| Late Relapse in Patients Initially Presenting with Advanced Stage Germ Cell Tumors | 362 | ||
| Histopathology of Late Relapse | 363 | ||
| Prognosis and multidisciplinary treatment of late relapse | 363 | ||
| Prognosis | 363 | ||
| Surgical Management | 364 | ||
| Salvage Chemotherapy | 365 | ||
| Summary | 365 | ||
| References | 366 | ||
| Role of Extraretroperitoneal Surgery in Patients with Metastatic Germ Cell Tumors | 369 | ||
| Key points | 369 | ||
| Introduction | 369 | ||
| Patterns of disease | 370 | ||
| Pathology | 370 | ||
| Extraretroperitoneal Disease | 370 | ||
| Concordance Rates | 371 | ||
| Surgical considerations | 371 | ||
| Lung | 371 | ||
| Mediastinum | 373 | ||
| Neck | 373 | ||
| Liver | 373 | ||
| Brain | 374 | ||
| Concurrent surgery | 374 | ||
| Outcomes | 375 | ||
| All Extraperitoneal Sites | 375 | ||
| Lung | 376 | ||
| Mediastinum | 376 | ||
| Neck | 377 | ||
| Liver | 377 | ||
| Brain | 377 | ||
| Postoperative chemotherapy | 378 | ||
| Summary | 378 | ||
| References | 378 | ||
| Reoperative Retroperitoneal Surgery | 381 | ||
| Key points | 381 | ||
| Introduction | 381 | ||
| Testicular tumors and patterns of metastasis | 382 | ||
| Incidence, distribution, and histologic findings of retroperitoneal recurrences | 382 | ||
| Histologic findings at reoperative retroperitoneal surgery | 385 | ||
| Indications for reoperative retroperitoneal surgery | 386 | ||
| Clinical outcomes | 386 | ||
| Perioperative morbidity and complications | 388 | ||
| Summary | 390 | ||
| References | 390 | ||
| Long-term Morbidity of Testicular Cancer Treatment | 393 | ||
| Key points | 393 | ||
| Introduction | 393 | ||
| Second malignant neoplasms | 394 | ||
| Pathogenesis | 394 | ||
| Risks of Leukemia | 394 | ||
| Risks of Solid Cancers | 394 | ||
| Management | 395 | ||
| Cardiovascular disease and Raynaud phenomenon | 395 | ||
| Pathogenesis | 395 | ||
| Risks | 395 | ||
| Management | 398 | ||
| Pulmonary toxicity | 399 | ||
| Infertility with Testicular Cancer | 409 | ||
| Key points | 409 | ||
| Introduction | 409 | ||
| Discussion: diagnosis of male Infertility | 409 | ||
| Relationship between infertility and testicular cancer | 410 | ||
| Systemic Effects of Testicular Cancer | 411 | ||
| Endocrine Effects of Testicular Cancer | 411 | ||
| Autoimmune Effects of Testicular Cancer | 411 | ||
| Abnormal Testicular Development | 412 | ||
| Cancer treatment and fertility | 413 | ||
| Surveillance | 413 | ||
| Retroperitoneal Lymph Node Dissection | 414 | ||
| Radiotherapy | 414 | ||
| Chemotherapy | 414 | ||
| Psychological and Sexual Effects of Cancer | 415 | ||
| Fertility preservation and infertility options | 416 | ||
| Cryopreservation | 416 | ||
| Postpuberty Adolescent Male Fertility Options | 417 | ||
| Prepubertal | 417 | ||
| Summary | 418 | ||
| References | 418 | ||
| Index | 421 |